- Home
- ECO vs GHRS Comparison
ECO vs GHRS Comparison
Compare ECO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- GHRS
- Stock Information
- Founded
- ECO 2018
- GHRS 2018
- Country
- ECO Greece
- GHRS Ireland
- Employees
- ECO N/A
- GHRS N/A
- Industry
- ECO
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- GHRS Health Care
- Exchange
- ECO Nasdaq
- GHRS Nasdaq
- Market Cap
- ECO 1.0B
- GHRS 839.9M
- IPO Year
- ECO N/A
- GHRS 2021
- Fundamental
- Price
- ECO $38.31
- GHRS $14.06
- Analyst Decision
- ECO Strong Buy
- GHRS Strong Buy
- Analyst Count
- ECO 2
- GHRS 10
- Target Price
- ECO $37.00
- GHRS $29.90
- AVG Volume (30 Days)
- ECO 231.4K
- GHRS 387.9K
- Earning Date
- ECO 11-12-2025
- GHRS 11-06-2025
- Dividend Yield
- ECO 5.52%
- GHRS N/A
- EPS Growth
- ECO N/A
- GHRS N/A
- EPS
- ECO 2.38
- GHRS N/A
- Revenue
- ECO $349,886,578.00
- GHRS N/A
- Revenue This Year
- ECO N/A
- GHRS N/A
- Revenue Next Year
- ECO $21.20
- GHRS N/A
- P/E Ratio
- ECO $15.92
- GHRS N/A
- Revenue Growth
- ECO N/A
- GHRS N/A
- 52 Week Low
- ECO $17.91
- GHRS $6.72
- 52 Week High
- ECO $39.77
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ECO 73.43
- GHRS 52.55
- Support Level
- ECO $32.86
- GHRS $13.35
- Resistance Level
- ECO $39.77
- GHRS $15.31
- Average True Range (ATR)
- ECO 0.92
- GHRS 1.04
- MACD
- ECO 0.37
- GHRS 0.05
- Stochastic Oscillator
- ECO 81.07
- GHRS 56.02
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.